GRAMD1A and cervical squamous cell carcinoma: High expression of GRAMD1A predicted poorer OS and relapse-free survival (RFS) for most cancers, including kidney cancer, cervical squamous cell carcinoma, liver cancer, and lung squamous carcinoma, especially in KIRC patients (Figure 4).